

CLAIMS:

1. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2873), or a salt thereof.

~~2. A modified oligonucleotide according to the following chemical structure:~~




~~(SEQ ID NO: 2752), or a salt thereof.~~

~~3. A modified oligonucleotide according to the following chemical structure:~~




~~(SEQ ID NO: 765), or a salt thereof.~~

4. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 1949), or a salt thereof.

~~5. A modified oligonucleotide according to the following chemical structure:~~



~~(SEQ ID NO: 2751), or a salt thereof.~~


~~6. A modified oligonucleotide according to the following chemical structure:~~



~~(SEQ ID NO: 2866), or a salt thereof.~~


~~7~~2. The modified oligonucleotide of ~~any of claims 1-6~~claim 1, which is the sodium salt or the potassium salt.

~~83~~. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2873).

9. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2752).

~~10. A modified oligonucleotide according to the following chemical structure:~~




~~(SEQ ID NO: 765).~~

~~11. A modified oligonucleotide according to the following chemical structure:~~




~~(SEQ ID NO: 1949).~~

12. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2751).

~~13. A modified oligonucleotide according to the following chemical structure:~~



~~(SEQ ID NO: 2866).~~

~~14~~4. A pharmaceutical composition comprising the modified oligonucleotide of ~~any one of claims 1-6~~claim 1 and a pharmaceutically acceptable diluent.

~~15~~5. The pharmaceutical composition of claim ~~14~~4, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

~~16~~6. The pharmaceutical composition of claim ~~15~~5, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

~~17~~7. A pharmaceutical composition comprising the modified oligonucleotide of ~~any one of claims 8-13~~claim 3 and a pharmaceutically acceptable diluent.

~~18~~8. The pharmaceutical composition of claim ~~17~~7, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

~~19~~9. The pharmaceutical composition of claim ~~18~~8, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

~~20~~10. A compound comprising a modified oligonucleotide according to the following chemical notation: $A_{es}{}^{m}C_{eo}{}^{m}C_{eo}A_{eo}T_{eo}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{ds}{}^{m}C_{ds}T_{eo}T_{eo}A_{es}G_{es}{}^{m}C_{e}$ (SEQ ID NO: 2873), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

~~21. A compound comprising a modified oligonucleotide according to the following chemical notation: $T_{es}T_{eo}{}^{m}C_{eo}A_{eo}{}^{m}C_{eo}{}^{m}C_{eo}A_{ds}T_{ds}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{eo}{}^{m}C_{es}T_{es}T_{e}$ (SEQ ID NO: 2752), wherein:~~

~~A = an adenine nucleobase,~~
~~mC = a 5-methyl cytosine nucleobase,~~
~~G = a guanine nucleobase,~~
~~T = a thymine nucleobase,~~
~~e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,~~
~~d = a 2'-β-D-deoxyribosyl sugar moiety,~~
~~s = a phosphorothioate internucleoside linkage, and~~
~~o = a phosphodiester internucleoside linkage.~~

~~22. A compound comprising a modified oligonucleotide according to the following chemical notation: $G_{es}{}^{m}C_{eo}A_{eo}T_{eo}A_{eo}{}^{m}C_{eo}{}^{m}C_{ds}{}^{m}C_{ds}A_{ds}G_{ds}G_{ds}G_{ds}T_{ds}A_{ds}G_{ds}G_{ds}A_{eo}T_{es}T_{es}{}^{m}C_{e}$ (SEQ ID NO: 765), wherein:~~

~~A = an adenine nucleobase,~~
~~mC = a 5-methyl cytosine nucleobase,~~
~~G = a guanine nucleobase,~~
~~T = a thymine nucleobase,~~
~~e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,~~
~~d = a 2'-β-D-deoxyribosyl sugar moiety,~~
~~s = a phosphorothioate internucleoside linkage, and~~

o = a phosphodiester internucleoside linkage.

23. A compound comprising a modified oligonucleotide according to the following chemical notation: $^{m}C_{es}A_{eo}T_{eo}{}^{m}C_{eo}A_{eo}T_{ds}G_{ds}A_{ds}T_{ds}{}^{m}C_{ds}T_{ds}T_{ds}G_{ds}G_{ds}T_{ds}A_{eo}A_{eo}G_{es}G_{es}{}^{m}C_{e}$ (SEQ ID NO: 1949), wherein:

A = an adenine nucleobase,

mC = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,

d = a 2'-β-D-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

24. A compound comprising a modified oligonucleotide according to the following chemical notation: $T_{es}{}^{m}C_{eo}A_{eo}{}^{m}C_{eo}{}^{m}C_{eo}A_{eo}T_{ds}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{ds}{}^{m}C_{eo}T_{es}T_{es}A_{e}$ (SEQ ID NO: 2751), wherein:

A = an adenine nucleobase,

mC = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,

d = a 2'-β-D-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

25. A compound comprising a modified oligonucleotide according to the following chemical notation: $A_{es}{}^{m}C_{eo}G_{eo}{}^{m}C_{es}A_{ds}A_{ds}T_{ds}G_{ds}T_{ds}A_{ds}T_{ds}{}^{m}C_{ds}A_{eo}G_{eo}G_{eo}{}^{m}C_{es}A_{es}A_{e}$ (SEQ ID NO: 2866), wherein:

A = an adenine nucleobase,

mC = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,

d = a 2'-β-D-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

~~26~~11. A pharmaceutical composition comprising the compound of ~~any one of claims 20-25~~claim 10, and a pharmaceutically acceptable diluent.

~~27~~12. The pharmaceutical composition of claim ~~26~~11, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

~~28~~13. The pharmaceutical composition of claim ~~27~~12, wherein the pharmaceutical composition consists essentially of the compound and artificial cerebrospinal fluid.

~~29~~14. The compound of ~~any one of claims 20-25~~claim 10, comprising the modified oligonucleotide covalently linked to a conjugate group.

~~30~~15. A pharmaceutical composition comprising the compound of claim ~~29~~14, and a pharmaceutically acceptable diluent.

~~31~~16. The pharmaceutical composition of claim ~~30~~15, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

~~32~~17. The pharmaceutical composition of claim ~~31~~16, wherein the pharmaceutical composition consists essentially of the compound and artificial cerebrospinal fluid.